Metastatic breast cancer trials recruiting in Massachusetts

All Metastatic breast cancer trials nationally

Cities in Massachusetts

Recruiting trials in Massachusetts

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
  NCT06099769 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer
  NCT07524855 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · Massachusetts: Boston
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
  NCT05894239 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Comprehensive Outcomes for After Cancer Health
  NCT05349227 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
  NCT07198724 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
  NCT06551220 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: Female · Massachusetts: Boston
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
  NCT05696626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Burlington
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
  NCT07222215 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
  NCT06784193 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · Massachusetts: Boston
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Scalp Cooling in MBC
  NCT04986579 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
  NCT06795529 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
  NCT06377852 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · Massachusetts: Boston, Foxborough, Methuen, Milford
• The COMPASSION Study
  NCT06507930 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston